今天3分钟我们来聊聊CAR-T治疗困境与通用型新希望

传统CAR-T治疗面临贵、慢、部分患者无法采集细胞的困境。通用型CAR-T用健康供体T细胞，可随取随用，中国企业在该领域进展靠前，但持久性和实体瘤治疗仍是挑战。参考资料科济生物 CT0596 通用型BCMA CAR-T：IIT研究，8例入组，第4周评估5例，sCR/CR 60%（3/5），MRD阴性80%（4/5），病灶分别减少92%和65%+北恒生物 RD13-02 通用型CD7 CAR-T：I期临床（EHA 2024），12例患者CR/CRi率92%（11/12），未观察到GvHD/神经毒性/DLT邦耀生物 BRL-303：Nature 2024.10，Cell 2025.01，成功治疗3名硬皮症患者全球UCAR-T临床试验：截至2024年10月共169项（Trialtrove数据库）前往小宇宙评论区与主播互动

Episode metadata supplied by the publisher feed · Published Apr 29, 2026

Embed this episode

Attribution link and audio player

Ready to play

今天3分钟我们来聊聊CAR-T治疗困境与通用型新希望

0:00 5:35

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

峰人学院

Frequently Asked Questions

How long is this episode of 源于细胞BioInsid的个人播客?

This episode is 5 minutes long.

When was this 源于细胞BioInsid的个人播客 episode published?

This episode was published on April 29, 2026.

Can I download this 源于细胞BioInsid的个人播客 episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!